ImmuDyne Forecasts Record Third Quarter 2017 Revenue
20 September 2017 - 10:00PM
ImmuDyne, Inc. (OTCQB:IMMD) (“ImmuDyne” or the “Company”), a leader
in the development and online marketing of OTC health and wellness
products addressing large unmet needs, today announced that it
expects record revenue in the third fiscal quarter of 2017.
ImmuDyne, Inc. reported unaudited Gross Revenue of
$623,000 in the month of July and $738,000 in unaudited Gross
Revenue in the month of August. Third quarter unaudited
revenue numbers, which will include the month of September, will be
released no later than October 15, 2017. The majority of
revenue growth in the second quarter came from ImmuDyne’s online
direct-response marketing business. The Company anticipates
continued double digit quarter-over-quarter revenue growth from its
new Shapiro MD product line, as well as from 2 new products that
will be launched in the fourth quarter of 2017.
“We are extremely pleased with the traction we’ve seen this
quarter, especially with Shapiro MD,” stated Mark McLaughlin, CEO
of Immudyne. “Although it’s great to be able to announce record
revenue numbers, we believe this is only the beginning for the
Shapiro MD product line and for our online direct-response
marketing business.”
About Shapiro MD™
The Shapiro MD product line is the result of 15 years of
research and development by thought-leading dermatologists Dr.
Steven Shapiro and Dr. Michael Borenstein. It is protected by
two U.S. patents and is the only product in the hair loss vertical
that contains what we believe are the 3 most powerful,
naturally-occurring dihydrotestosterone (DHT) blocking
ingredients. DHT is widely believed to be the main culprit of
balding/hair-loss. For more information on Shapiro MD or to
purchase the product, please visit www.shapiromd.com.
About lmmudyne
lmmudyne, Inc. (the "Company") is a health and wellness company
that develops, manufactures, and markets innovative consumer
products. Immudyne manufactures and markets a proprietary and
patent protected Yeast Beta Glucan that has been shown in thousands
of clinical studies to support and regulate the human immune
system. It has broad applications in skincare and as an
immune support supplement. Immudyne PR, a majority owned
subsidiary of ImmuDyne, Inc., is the digital marketing arm of
Immudyne and is currently focused on marketing products for thicker
and fuller hair (Shapiro MD) and a skincare line containing
Immudyne’s proprietary Yeast Beta Glucan ingredient (Inate
MD). All of lmmudyne's intellectual property is protected by
patents and/or trade secrets. Additional information can be found
on the web at www.immudyne.com
Forward-Looking Statements Cautionary language regarding
Forward-Looking Statements Safe Harbor Act Disclaimer: Forward
looking statements in this release are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. Certain statements in this press release, including
projections with respect to lmmuDyne's results of operations, may
contain words such as "anticipates," "believes," "could,"
"estimates," "expects," "intends," "may," "projects,"
"plans," "targets" and other similar language and are
considered forward-looking statements. These statements are based
on management's current expectations, estimates, and forecasts.
These forward-looking statements are subject to important
assumptions, risks and uncertainties, which are difficult to
predict and therefore the actual results may be materially
different from those discussed.
The preliminary, unaudited information provided above is based
on the Company’s current estimate of results from operations for
the second quarter and its cash at June 30, 2017, and remains
subject to change based on the Company’s closing procedures,
including the subsequent occurrence or identification of events
prior to the formal issuance of the quarterly financial
statements.
Contact:ImmuDyne, Inc.Bernard Girma
+1-949-215-7754bfgirma@immudyne.com